BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27393041)

  • 1. Authors' response to the letter by Dr. Eisa-Beygi.
    Reinhard M; Schuchardt F; Meckel S; Heinz J; Felbor U; Sure U; Geisen U
    J Neurol Sci; 2016 Oct; 369():392. PubMed ID: 27393041
    [No Abstract]   [Full Text] [Related]  

  • 2. A call for rigorous study of statins in resolution of cerebral cavernous malformation pathology.
    Eisa-Beygi S; Wen XY; Macdonald RL
    Stroke; 2014 Jun; 45(6):1859-61. PubMed ID: 24803598
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter by Filippidis et al regarding article, "Evaluating strategies for the treatment of cerebral cavernous malformations".
    Filippidis AS; Fountas KN; Kalani MY; Zabramski JM; Spetzler RF
    Stroke; 2011 May; 42(5):e373. PubMed ID: 21393598
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose simvastatin for aneurysmal subarachnoid hemorrhage.
    Chu Wong GK; Poon WS
    Neurosurgery; 2013 Sep; 73(3):E561-2. PubMed ID: 23756754
    [No Abstract]   [Full Text] [Related]  

  • 5. [Letter].
    Poli A
    G Ital Cardiol (Rome); 2015 Dec; 16(12):739-40. PubMed ID: 26667952
    [No Abstract]   [Full Text] [Related]  

  • 6. Simvastatin may be a useful therapy in Dupuytren contracture.
    Namazi H; Emami MJ
    Med Hypotheses; 2006; 66(3):683-4. PubMed ID: 16343796
    [No Abstract]   [Full Text] [Related]  

  • 7. Simvastatin and cerebral cavernous malformations (Re: Reinhard et al., 2016).
    Eisa-Beygi S
    J Neurol Sci; 2016 Oct; 369():391. PubMed ID: 27389298
    [No Abstract]   [Full Text] [Related]  

  • 8. Are statins to be STASHed in subarachnoid haemorrhage?
    Macdonald RL
    Lancet Neurol; 2014 Jul; 13(7):639-41. PubMed ID: 24837689
    [No Abstract]   [Full Text] [Related]  

  • 9. Simvastatin administration.
    Patel A
    Am J Nurs; 2012 Aug; 112(8):20. PubMed ID: 22832450
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential advantages of simvastatin as a novel anti-vitiligo arsenal.
    Feily A; Baktash D; Mohebbipour A; Feily A
    Eur Rev Med Pharmacol Sci; 2013 Jul; 17(14):1982-3. PubMed ID: 23877867
    [No Abstract]   [Full Text] [Related]  

  • 11. Simvastatin and plaque inflammation.
    Rudd JH; Machac J; Fayad ZA
    J Am Coll Cardiol; 2007 May; 49(19):1991; author reply 1991-2. PubMed ID: 17498586
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Letter: "Effect of Simvastatin on Physiological and Biological Outcomes in Patients Undergoing Esophagectomy: A Randomized Placebo-controlled Trial".
    Shyamsundar M; McAuley DF; O'Kane CM
    Ann Surg; 2015 Dec; 262(6):e95-6. PubMed ID: 24743618
    [No Abstract]   [Full Text] [Related]  

  • 13. A patient with hyper-IgD syndrome responding to simvastatin treatment.
    Attout H; Guez S; Ranaivo I; Jameerbaccus N; Series C
    Eur J Intern Med; 2008 Dec; 19(8):e82-3. PubMed ID: 19046710
    [No Abstract]   [Full Text] [Related]  

  • 14. Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.
    Tenenbaum A; Fisman EZ; Motro M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1978; author reply 1978-9. PubMed ID: 15070976
    [No Abstract]   [Full Text] [Related]  

  • 15. Simvastatin in moderate-to-severe COPD.
    Suissa S
    N Engl J Med; 2014 Sep; 371(10):969-70. PubMed ID: 25184880
    [No Abstract]   [Full Text] [Related]  

  • 16. Simvastatin in moderate-to-severe COPD.
    Egom EE
    N Engl J Med; 2014 Sep; 371(10):969. PubMed ID: 25184879
    [No Abstract]   [Full Text] [Related]  

  • 17. Simvastatin in moderate-to-severe COPD.
    Criner GJ; Connett JE; Voelker H
    N Engl J Med; 2014 Sep; 371(10):970-1. PubMed ID: 25184878
    [No Abstract]   [Full Text] [Related]  

  • 18. [Simvastatin].
    TaƩron C
    Rev Infirm; 2003 May; (91):39-40. PubMed ID: 12827760
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
    Kotyla PJ; Sliwinska-Kotyla B; Kucharz EJ
    J Rheumatol; 2006 Nov; 33(11):2361-3; author reply 2363. PubMed ID: 17086617
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
    Kumar A; Sharma N; Gupta A; Kalonia H; Mishra J
    Brain Res; 2012 Aug; 1471():13-22. PubMed ID: 22789904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.